Grant Gallagher;Nicholas Megjugorac;Grant E. Gallagher
发明人:
Grant Gallagher,Nicholas Megjugorac,Grant E. Gallagher
申请号：
US12592635
公开号：
US08282964B2
申请日:
2009.11.30
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-λ). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-λ in an effective amount to inhibit cytokine releases. The IFN-λ exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-λ treatment of pDC, in conjunction with co-administration of a composition comprising IFN-λ.
